INTRODUCTION
containing anti-cathepsin K was coated onto 96-well plates (ICN Biomedicals, Aurora, OH, USA). The test supernatants (100-10000x dilution) were applied, followed by HRP-conjugated antihuman cathepsin K. The concentration of cathepsin K in the test solution was interpolated from the standard curve generated from the standard antigen solution.
Cycloheximide and Actinomycin D Study
Mature osteoclasts (approximately 5 x 10 4 ) were treated with 10 g/mL cycloheximide (CHX; Sigma, St. Louis, MO, USA) or 5 g/mL actinomycin D (Act D; Sigma, St. Louis, MO, USA) and then exposed to IL-1␣ (1.4 nM; Genzyme Corporation, Cambridge, MA, USA) an hour later. In parallel, control cells were treated with PBS for 1 hr before being exposed to IL-1␣.
Cathepsin K Promoter Constructs
A cathepsin K promoter-CAT fusion gene (pMCCAT) containing a 1978-bp XbaI/EcoRI fragment (-1400 to +357, numbered relative to the cap site) of the mouse cathepsin K 5Ј-flanking region was used as to generate the cathepsin K promoter CAT fusion gene construct. The XbaI/EcoRI fragment was subcloned into pCAT-3 Basic reporter vector (Promega, Madison, WI, USA) to produce the cathepsin K promoter constructs and named pMCCAT-1400.
DNA Transfection and CAT (Chloramphenicol acetyltransferase) Assay
Transient transfection of plasmid DNA into MOCP-5 was performed with the lipofectAMINE reagent (Invitrogen, Gaithersburg, MD, USA) as described (Chen and Li, 1998) . In all experiments, the effect of IL-1␣ (250 U/mL or 1.4 nM) on pMCCAT-1400 promoter activity was tested in triplicate, either with or without RANKL (20 ng/mL). CAT assays were performed on lysates as described (Neumann et al., 1987) . CAT activity in transfected cultures was standardized by normalization to ␤galactosidase activity of cotransfected pSV-␤-galactosidase constructs (Promega, Madison, WI, USA) (Li and Stashenko, 1993) . CAT assay results were standardized to the protein concentration of cell layer extracts by means of a protein assay kit (Bio-Rad, Richmond, CA, USA).
Signaling Pathway Inhibitor Studies
When OCLs were fully developed, the following signaling pathway inhibitors were added: 100 M PDTC (pyrrolidine dithiocarbamate, from Sigma, St. Louis, MO, USA) dissolved in water, 100 M Genistein (Sigma, St. Louis, MO, USA), 20 M SB 203580 (Calbiochem, La Jolla, CA, USA), and 20 M PD 98059 (Biomol, Plymouth Meeting, PA, USA) dissolved in DMSO (dimethylsulfoxide, Sigma, St. Louis, MO, USA). After 2 hrs of culturing with these inhibitors, IL-1␣ (125 U/mL or 0.7 nM) was added. The medium was discarded 6 hrs later. The OCL population was washed in PBS, and total RNA was then isolated.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extraction was performed as described (Li et al., 1995) . The sequence of the NF-B binding oligonucleotide used as a radioactive DNA probe was 5Ј-AGCTTGGGGACTTTCCGAC-3Ј.
Antisense Oligodeoxynucleotide Studies
We performed antisense blocking experiments to characterize and confirm that IL-1␣ acts through NF-B to regulate cathepsin K expression as described (Jimi et al., 1998) . In brief, when OCLs were fully developed on day 5, the sense and antisense oligonucleotides were added (see Table for oligo sequences): p50 antisense (5 M) and p65 antisense (10 M). Prior to that addition, we mixed 100 nM Tfx TM -50 (Promega, Madison, WI, USA), polycationic liposome, with these antisense oligonucleotides as the S-ODN (synthetic phosphorothioate oligodeoxynucleotides), as previously described (Inui et al., 1997) . After nine-hour incubation with these antisense oligonucleotides, IL-1␣ (0.7 nM) was added. Control cells received an equal (Jimi et al., 1998) 
Gene
Sequences* Nucleotide p50 sense 5Ј-CTGCGCATCTTCACCATGGCA-3Ј 277-297 p50 antisense 5Ј-TGCCATGGTGAAGATGCGCAG-3Ј p65 sense 5Ј-GGGACCCTGACCATGGACGAT-3Ј 49-69 p65 antisense 5Ј-ATCGTCCATGGTCAGGGTCCC-3Ј * The oligodeoxynucleotide sequences correspond to the 5Ј ends of respective mRNAs and include 3 or 4 nucleotides present upstream of the initiation codon. concentration of corresponding sense oligonucleotides or just fresh medium without oligonucleotides. After 6 hrs of culture, the medium was discarded. The OCL population was washed in PBS, total RNA was isolated, and Northern blot analysis was carried out as described above. The expression of p50 or p65 mRNA was detected by RT-PCR with the use of gene-specific PCR primers as described (Jimi et al., 1998) .
Statistical Analysis
Statistical significance was evaluated by the Student's t test.
The results were considered significant for p < 0.05.
RESULTS

IL-1␣ ␣ Up-regulates Cathepsin K Protein
We examined whether IL-1␣ upregulates cathepsin K protein expression in osteoclasts by using osteoclast-like cells (OCLs) which derived from MOCP-5 (Chen and Li, 1998) , or mouse bone marrow cells. Using the ELISA technique, we found that incubating OCLs with IL-1␣ (250 U/mL or 1.4 nM) for 10 and 15 hrs increased cathepsin K protein production by about three-and four-fold, respectively, compared with controls ( Fig. 1A) . We then examined the effects of IL-1␣ on inducing bone-resorbing activity of osteoclasts by a dentin resorption assay. Fig. 1B shows the resorption pits formed by OCLs in the absence (a) or presence (b) of IL-1␣. It has been demonstrated that the resorbed surface area is a suitable parameter in studies of osteoclasts to quantitate pit formation (Chen and Li, 1998) . As shown in Fig.  1C , incubating OCLs with IL-1␣ increased the resorbed surface area by about 2.5-fold, compared with controls, indicating that IL-1␣ significantly increased the pit-forming activity of OCLs.
IL-1␣ ␣ Up-regulates the mRNA Levels of Cathepsin K in a Dose-responsive and Time-dependent Manner at the Transcription Level
To determine whether IL-1␣ up-regulates cathepsin K expression at the transcriptional level, we examined cathepsin K mRNA levels following IL-1␣ application. IL-1␣ (1.4 nM)
was found to increase cathepsin K mRNA levels by two-fold in the MOCP-5 and stromal cells co-culture system (Chen and Li, 1998) , two-fold in the bone marrow cells co-culture system, and 2.5-fold in osteoclast-like cells derived from MOCP-5 cells induced by RANKL, respectively, within 6 hrs, as determined by Northern analysis ( Figs. 2A, 2B ). We used the MOCP-5 coculture system in all other experiments. A time-course examining cathepsin K expression following IL-1␣ (1.4 nM) treatment showed that cathepsin K mRNA levels peaked at 6 hrs (Figs. 2C, 2D ). As the concentration of IL-1␣ treatment was increased, cathepsin K expression steadily rose to an IL-1␣ concentration of 14 nM, where it reached a plateau ( Figs. 2E,  2F) . These findings indicate that IL-1␣ regulates cathepsin K expression in a time-dependent and dose-responsive manner.
To determine whether IL-1␣ regulated cathepsin K expression through inducing protein expression or regulating DNA transcription, we first pre-treated mature osteoclasts in the MOCP-5 cell co-culture system, that were exposed to IL-1␣, with 10 g/mL cycloheximide (CHX), a protein synthesis inhibitor, or actinomycin D (Act D), a transcription blocker. CHX failed to prevent the IL-1␣-induced increase in cathepsin K expression ( Figs. 2G, 2H) , indicating that no new protein was required for this induction. Moreover, mature osteoclasts treated with Act D blocked the IL-1␣-induced increase in cathepsin K mRNA (Figs. 2G, 2H) , indicating that IL-1␣ upregulates cathepsin K expression at the transcription level.
IL-1␣ ␣ Up-regulates the Cathepsin K Promoter-CAT Fusion Gene Only in Mature Osteoclast Cells
To determine whether the cathepsin K promoter is the region that IL-1␣ uses to regulate cathepsin K transcription, we performed transfection studies with a cathepsin K promoter-CAT fusion gene (pMCCAT). Pre-osteoclast (MOCP-5) and mature osteoclast cells were transiently transfected with pMCCAT by means of the lipofectAMINE reagent, and reporter CAT activity was determined following IL-1␣ treatment. In mature osteoclast cells, CAT activity was up-regulated approximately threefold in response to 7 hrs of IL-1␣ treatment, compared with controls (Fig. 3A) , and no effect was observed in pre-osteoclast cells, indicating that the IL-1␣ signal acted on the cathepsin K promoter region, and this action occurred only in mature osteoclast cells.
NF-B Activation Inhibitor and Tyrosine Kinase Inhibitor Inhibit the Induction of IL-1␣ ␣ on Cathepsin K Gene Expression
To characterize the signaling pathway that is used by IL-1␣ to regulate cathepsin K expression, we used signaling pathway inhibitors in our study: an NF-B activation inhibitor (PDTC), a tyrosine kinase inhibitor (Genistein), and 2 mitogenactivated protein kinase (MAPK) pathway inhibitors (pyridinylimidazole, SB 203580, a specific inhibitor of p38 mitogen-activated and 2Ј-amino-3Ј-methoxyflavone, PD 98059, for MEK/ERK inhibition). The MAPK pathway inhibitors showed no effect on cathepsin K expression following IL-1␣ treatment (Figs. 3B, 3C). In contrast, after pre-treatment with either NF-B activation inhibitor or tyrosine kinase inhibitor for 2 hrs, the up-regulation of cathepsin K mRNA level was completely blocked, as determined 6 hrs after IL-1␣ treatment (Figs. 3B,  3C ). This suggests that IL-1␣ regulates cathepsin K expression via the tyrosine kinase-NF-B signal pathway.
IL-1␣ ␣ Activates NF-B in Osteoclasts
The DNA-binding activation of NF-B was strongly detected in nuclear extracts derived from OCLs following 30 min of induction by IL-1␣ (Fig. 4A, lane 3) . The binding activity was partially reduced with 10-fold (lane 4) and almost completely diminished with 100-fold excess unlabeled NF-B binding oligonucleotide (lane 5), signifying specific binding. These findings indicate that NF-B is activated in response to IL-1␣ stimulation, and that IL-1␣ activates NF-B in osteoclasts.
p65 but not p50 is Responsible for the Transcription Activation of NF-B.
The activated nuclear form of the NF-B transcription factor binds to DNA as a heterodimer of 50-kDa (p50) and 65-kDa (p65) polypeptides. We performed antisense blocking experiments further to characterize and confirm that IL-1␣ acts through NF-B to regulate cathepsin K expression as described (Jimi et al., 1998) . When MOCP-5 cells were treated with the antisense S-ODNs to p50 or p65, expression of the respective mRNA by MOCP-5 cells was suppressed (Fig. 4B) . MOCP-5 cells pre-treated with antisense oligonucleotides to the p65 subunit of NF-B suppressed the increase in cathepsin K expression by IL-1␣ approximately 45% compared with controls ( Figs. 4C, 4D) . In contrast, MOCP-5 cells pre-treated with antisense oligonucleotides to the p50 subunit of NF-B showed no effect.
DISCUSSION
IL-1␣ activates several signaling cascades, including Akt and ERK (Lee et al., 2002) , NF-B (Jimi et al., 1996; Miyazaki et al., 2000) , and JNK (Jimi et al., 1999) pathways. It has been suggested that ERK is responsible for osteoclast survival, whereas NF-B regulates osteoclast activation for bone resorption (Miyazaki et al., 2000) . However, it is not well-known what downstream genes are induced after IL-1␣ stimulation to promote osteoclastic bone resorption. In the present study, we found that IL-1␣ up-regulated cathepsin K expression via the NF-B pathway.
In the CAT assay, no increase of CAT activity response to IL-1␣ was observed in pre-osteoclast cells. This result is consist with our previous finding that cathepsin K mRNA was not detected in pre-osteoclast cells (Li and Chen, 1999) . Osteopetrosis in NF-B1 and NF-B2 double-knockout mice has identified an important role for NF-B in osteoclast differentiation (Iotsova et al., 1997) . In this study, NF-B was activated in response to IL-1␣ stimulation, a result consistent with that of Jimi et al. (1996) . Furthermore, NF-B activation inhibitor or tyrosine kinase inhibitor completely blocked the increase of cathepsin K mRNA levels induced by IL-1␣ treatment. We had previously reported that there is an NF-B binding site, GGGACTGCCC, located in -8886 to -8877 of the cathepsin K promoter (Li and Chen, 1999) . Taken together, these results indicate that IL-1␣ up-regulates cathepsin K expression via the NF-B pathway.
The cycloheximide experiment showed that no new protein was needed to induce cathepsin K expression. However, cathepsin K expression could not be induced when p65 subunits of NF-B protein synthesis were blocked in an antisense study. Similar results, in which antisense Hsp60 oligonucleotides reduced Hsp60 expression, while cycloheximide was used to inhibit protein synthesis, did not alter the effect of Hsp60 on IGF-1R signaling, and IGF-1R mRNA levels were not up-regulated by Hsp10 or Hsp60 (Shan et al., 2003) . It is possible that CHX inhibited synthesis of all cellular proteins, including proteinases, so p65 is relatively stable to perform IL-1␣ response stimulation. While cells lack both original p65, due to protein degradation, and new p65 synthesis, due to antisense treatment, blocking failed to respond to IL-1␣.
Our results also demonstrate that pre-treatment with antisense oligonucleotides to p65, but not p50, suppresses the upregulation effect of IL-1␣ on cathepsin K expression in osteoclasts. This indicates that the p65, but not the p50, subunit of NF-B is responsible for the transcriptional regulation of cathepsin K expression induced by IL-1␣. This finding is consistent with p65, the DNA-binding component of NF-B, having the more critical role in initiating transcription, whereas p50 functions to assist in DNA binding (Schmitz and Baeuerle, 1991) and has a primary structure completely divergent from that of p65 (Nolan et al., 1991) . This finding is also consistent with the results of Xing et al. (2003) , that p50 and p52 subunits, which are highly homologous, can have overlapping functions in cell activation, as seen in the impaired osteoclast development only in double-knockout mice. Expression of either NF-B p50 or p52 in osteoclast precursors is required for IL-1␣-mediated formation of mature osteoclasts (Xing et al., 2003) .
The results of this study suggest the mechanism by which IL-1␣ activates bone resorption through its up-regulation on the expression of osteoclast genes. Our findings presented here will add to our understanding of the interplay between the local bone environment and the regulation of expression of osteoclast genes during the normal and pathological bone resorption process, and will help us identify additional targets for therapeutic intervention in bone disorders such as osteoporosis, osteoarthritis, rheumatoid arthritis, periodontal disease, and other bone disorders.
